The National Institute for Health and Care Excellence (NICE) has announced its decision to reject Fampyra – also known as fampridine – for use in England. The drug was developed by Acorda Therapeutics and is manufactured by Elan Corporation.
The treatment can significantly improve walking ability and quality of life for people with multiple sclerosis (MS), but will not be used across the NHS in England…
